Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events in Type 2 Diabetes: Results From the CANVAS Program

Similar documents
Retour sur le congrès de l AHA 2017

egfr > 50 (n = 13,916)

Paolo Fornengo SCDU Medicina Interna 3 AOU Città della Salute e della Scienza di Torino

Discussant Primary and Secondary Prevention of CV Events in the CANVAS Program

Top HF Trials to Impact Your Practice

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

CANVAS Program Independent commentary

Can We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists

6/26/2017. The CANVAS Program (CANagliflozin cardiovascular Assessment Study) Presenter Disclosures: Bruce Neal, MB ChB, PhD. Design.

Supplement materials:

Dapagliflozin and cardiovascular outcomes in type 2

The EMPA-REG OUTCOME trial: Design and results. David Fitchett, MD University of Toronto, Canada

Management of Type 2 Diabetes Cardiovascular Outcomes Trials Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas

Effect of SGLT-2 Inhibitors on the Heart. Robert Zimmerman MD Vice Chairman Endocrinology Director Diabetes Center Cleveland Clinic

01/09/2017. Outline. SGLT 2 inhibitor? Diabetes Patients: Complex and Heterogeneous. Association between diabetes and cardiovascular events

ADVANCE post trial ObservatioNal Study

Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease. Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.

Optimising the analysis strategy for the CANVAS Program a pre-specified plan for the integrated analyses of the CANVAS and CANVAS-R trials

The Role Of SGLT-2 Inhibitors In Clinical Practice. Anne Peters, MD Professor, USC Keck School of Medicine Director, USC Clinical Diabetes Programs

Updates in Diabetes and Cardiovascular Disease Management: Are You Making the Link?

Invokana (canagliflozin) NEW INDICATION REVIEW

STABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY. Harvey D White on behalf of The STABILITY Investigators

10-Year Mortality of Older Acute Myocardial Infarction Patients Treated in U.S. Community Practice

1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria

ACCP Cardiology PRN Journal Club

The earlier BP control the better cardiovascular outcome. Jin Oh Na Cardiovascular center Korea University Medical College

Presented by Terje R. Pedersen Oslo Disclosure: Research grants and/or speaker- / consulting fees from Merck, MSP, Astra-Zeneca, Pfizer

The Clinical Unmet need in the patient with Diabetes and ACS

Supplementary Appendix

Preventive Cardiology Scientific evidence

Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol

ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease

When Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes

CARDIO-RENAL SYNDROME

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam

LDL Cholesterol Lowering with Evolocumab and Outcomes in Patients with Peripheral Artery Disease: Insights from the FOURIER Trial

CVD risk assessment using risk scores in primary and secondary prevention

GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS

Predicting and changing the future for people with CKD

Randomized comparison of single versus double mammary coronary artery bypass grafting: 5 year outcomes of the Arterial Revascularization Trial

Update on Diabetes Cardiovascular Outcome Trials

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

Cardiovascular Outcomes With Newer Diabetes Drugs: Results From The EMPA-REG and LEADER Trials

Management of Cardiovascular Disease in Diabetes

Dapagliflozin and Outcomes in Patients with Peripheral Artery Disease: Insights from DECLARE-TIMI 58

JAMA. 2011;305(24): Nora A. Kalagi, MSc

Protecting the heart and kidney: implications from the SHARP trial

Diabetes and New Meds for Cardiovascular Risk Reduction. F. Dwight Chrisman, MD, FACC. Disclosures: BI Boehringer Ingelheim speaker

A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS

9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?

Update on Cardiovascular Outcome Trials in Diabetes Jay S. Skyler, MD, MACP

Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway

Causes of death in Diabetes

No Increased Cardiovascular Risk for Lixisenatide in ELIXA

Hypertension targets: sorting out the confusion. Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes

Treating Hypertension in 2018: What Makes the Most Sense Today?

Antihypertensive Trial Design ALLHAT

STATINS EVALUATION IN CORONARY PROCEDURES AND REVASCULARIZATION

Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus

CONFERENCE REPORT THE AMERICAN JOURNAL OF MANAGED CARE

Συμπεράσματα από τις νέες μελέτες για την αρτηριακή υπέρταση (SPRINT,PATHAY 2,HOPE 3)

Adult Diabetes Clinician Guide NOVEMBER 2017

Trial to Reduce. Aranesp* Therapy. Cardiovascular Events with

SGLT2 inhibition in diabetes: extending from glycaemic control to renal and cardiovascular protection

Drug Class Monograph

Microvascular Disease in Type 1 Diabetes

Update on CVD and Microvascular Complications in T2D

Data Analysis Plan for assessing clinical efficacy and safety of ER niacin/laropiprant in the HPS2-THRIVE trial

Quality Measures MIPS CV Specific

CARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial)

Cedars Sinai Diabetes. Michael A. Weber

Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications

Investor Conference Call

J-curve Revisited. An Analysis of Blood Pressure and Cardiovascular Events in the Treating to New Targets (TNT) Trial

Diabete: terapia nei pazienti a rischio cardiovascolare

The Burden of the Diabetic Heart

Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS) A randomized placebo-controlled trial

Lowering blood pressure (BP) in patients with type 2

7 th Munich Vascular Conference

A: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups

A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes

How would you manage Ms. Gold

Patient characteristics Intervention Comparison Length of followup

Diabetes and Hypertension

Sodium-glucose cotransporter 2 inhibitors and death and heart failure in type 2 diabetes

Macrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?

The Latest Generation of Clinical

New Therapies for Type 2 Diabetes

New Therapies for Type 2 Diabetes

CARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial)

1. How does the response to therapy compare in elderly versus middle age adults with diabetes in a randomized trial?

The ACCELERATE Trial

REVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease

Update sulla terapia antiipertensiva e antiaggregante nel paziente cardiometabolico

Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial

The Diabetes Link to Heart Disease

Transcription:

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events in Type 2 Diabetes: Results From the CANVAS Program Kenneth W. Mahaffey, Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Tao Sun, Mehul Desai, David R. Matthews, on behalf of the CANVAS Program collaborative group November 13, 2017

CANVAS Program CANVAS Program N = 10,142 CANVAS n = 4330 CANVAS-R n = 5812 2009 2010 2011 2012 2013 2014 2015 2016 2017 2-week placebo run-in R Canagliflozin 300 mg + Canagliflozin 100 mg Neal B. NEJM. 2017.

Participants Patients with type 2 diabetes HbA1c 7.0% to 10.5% egfr 30 ml/min/1.73 m 2 Secondary prevention: Age 30 years and history of prior CV event OR Primary prevention: Age 50 years with 2 CV risk factors* Of 10,142 patients enrolled 6656 (66%) secondary prevention 3486 (34%) primary prevention *Diabetes duration 10 years, SBP >140 mmhg on 1 medication, current smoker, micro- or macroalbuminuria, or HDL-C <39 mg/dl Neal B. NEJM. 2017.

CV and Renal Outcomes Hazard ratio (95% CI) CV death, nonfatal MI, or nonfatal stroke 0.86 (0.75, 0.97) p = 0.02 Hospitalization for heart failure 0.67 (0.52, 0.87) CV death or hospitalization for heart failure 0.78 (0.67, 0.91) All-cause mortality 0.87 (0.74, 1.01) Progression of albuminuria 0.73 (0.67, 0.79) Renal composite 0.60 (0.47, 0.77) 0.5 1.0 2.0 Favors Canagliflozin Favors Neal B. NEJM. 2017.

Methods Objective: To compare the effects of canagliflozin versus placebo on CV, renal, and safety outcomes among secondary and primary prevention participants Statistical methods Evaluation of outcomes in primary prevention and secondary prevention cohorts was prespecified Efficacy analyses used the intention-to-treat population Safety analyses used the on-treatment population Hazard ratios and 95% CIs were estimated for canagliflozin versus placebo separately for the primary prevention cohort and the secondary prevention cohort using Cox proportional hazards regression models stratified by study Risk differences were calculated by subtracting the incidence rate (per 1000 patient-years) with placebo from the incidence rate with canagliflozin

Baseline Characteristics Secondary prevention (n = 6656) Primary prevention (n = 3486) Mean age, y 64 63 Female, % 31 45 Mean duration of diabetes, y 13 14 Mean HbA1c, % 8.2 8.3 Hypertension, % 89 91 Antihyperglycemic agents, % 98 99 Cardioprotective agents, % RAAS inhibitor 80 81 Statin 81 63 Antithrombotic 87 49 Beta blocker 64 33 Diuretic 44 44

Baseline CV Disease History Secondary prevention (n = 6656) Primary prevention (n = 3486) Myocardial infarction 44 0.5 Hospitalization for USA 11 0 Coronary revascularization 54 0.1 PCI 38 0.1 CABG 21 <0.1 Stroke 19 0.4 Carotid revascularization 1 0 Peripheral revascularization (surgical or percutaneous) 8 0.1 Amputation 3 0.6 Data are percentage of participants.

Patients with an event (%) Patients with an event (%) CV Death, Nonfatal MI, or Nonfatal Stroke Secondary Prevention Primary Prevention 24 Hazard ratio 0.82 (95% CI: 0.72, 0.95) 24 Hazard ratio 0.98 (95% CI: 0.74, 1.30) 22 20 22 20 p-interaction = 0.18 18 18 16 16 14 14 12 12 10 10 8 8 6 6 4 2 0 0 Canagliflozin 1 2 3 4 5 6 4 2 0 Canagliflozin 0 1 2 3 4 5 6 Years since randomization Years since randomization

Patients with an event (%) Patients with an event (%) Hospitalization for HF Secondary Prevention Primary Prevention 8 Hazard ratio 0.68 (95% CI: 0.51, 0.90) 8 Hazard ratio 0.64 (95% CI: 0.35, 1.15) 7 Canagliflozin 7 Canagliflozin p-interaction = 0.91 6 6 5 5 4 4 3 3 2 2 1 1 0 0 1 2 3 4 5 6 0 0 1 2 3 4 5 6 Years since randomization Years since randomization

Patients with an event (%) Patients with an event (%) Renal Composite Outcome Secondary Prevention Primary Prevention 12 Hazard ratio 0.59 (95% CI: 0.44, 0.79) 12 Hazard ratio 0.63 (95% CI: 0.39, 1.02) 10 Canagliflozin 10 Canagliflozin p-interaction = 0.73 8 8 6 6 4 4 2 2 0 0 1 2 3 4 5 6 Years since randomization 0 0 1 2 3 4 5 6 Years since randomization Renal composite outcome includes 40% reduction in egfr, renal replacement therapy, or renal death.

Safety Events Male genital infections Female genital infections* Low-trauma fracture Volume depletion events* Hypoglycemia* Lower-extremity amputation Patients per 1000 patient-years Canagliflozin Secondary prevention Primary prevention Overall population Hazard ratio (95% CI) p-interaction 37 11 3.7 (2.7, 5.0) 0.83 41 11 4.0 (2.6, 6.1) 38 11 3.8 (3.0, 4.8) 82 20 4.0 (2.1, 7.5) 0.69 77 16 4.8 (2.5, 9.2) 79 18 4.4 (2.8, 6.9) 12 9 1.2 (0.9, 1.6) 0.85 11 9 1.2 (0.9, 1.8) 12 9 1.2 (1.0, 1.5) 31 23 1.4 (1.0, 1.9) 0.65 22 14 1.6 (1.0, 2.6) 27 19 1.4 (1.1, 1.9) 60 52 1.2 (0.9, 1.5) 0.52 51 50 1.0 (0.8, 1.4) 56 51 1.1 (0.9, 1.4) 9 4 2.1 (1.4, 3.0) 0.63 3 2 1.5 (0.7, 3.3) 6 3 2.0 (1.4, 2.7) 0.25 0.5 1 2 4 8 16 32 *Serious and nonserious adverse events of interest collected in CANVAS only. Favors Canagliflozin Favors

Benefit Risk: Risk Differences Number of patients Number of events prevented in 1000 patients over 5 years (95% CI) CV death, nonfatal MI, or nonfatal stroke Hospitalization for heart failure 796 36 (9, 63) 215 2 ( 23, 20) 1011 23 (4, 42) 198 20 (7, 33) 45 8 ( 2, 18) 243 16 (7, 25) 40% reduction in egfr, renal replacement therapy, or renal death Lower extremity amputation 179 21 (8, 33) 70 13 ( 0.5, 25) 249 18 (8, 27) 154 21 ( 31, 11) 33 5 ( 13, 3) 187 15 ( 22, 8) 40 20 0 20 40 60 80 Secondary prevention Primary prevention Overall population Harm Benefit

Limitations The trial was not designed with appropriate statistical power to show definitive treatment differences in the outcomes in primary and secondary prevention participants The primary and secondary prevention participants were categorized based on investigator-reported criteria Participants were not screened for subclinical atherosclerotic vascular disease, so those with asymptomatic CV disease may have been included in the primary prevention cohort

Conclusions In the CANVAS Program of patients with type 2 diabetes and elevated CV risk, Participants with prior CV events (secondary prevention) compared with those without prior CV events (primary prevention) had greater absolute rates of CV, renal, and death outcomes Canagliflozin reduced CV and renal outcomes overall, with no statistical evidence of heterogeneity of canagliflozin effects across the primary and secondary prevention participants Further study with longer follow-up in a primary prevention population will provide further insights into the effect of canagliflozin (CREDENCE) and other SGLT2 inhibitors (DECLARE)

DOI: 10.1161/CIRCULATIONAHA.117.032038 Kenneth W. Mahaffey, MD; Bruce Neal, MB, ChB, PhD; Vlado Perkovic, MBBS, PhD; Dick de Zeeuw, MD, PhD; Greg Fulcher, MD; Ngozi Erondu, MD, PhD; Wayne Shaw, DSL; Elisa Fabbrini, MD, PhD; Tao Sun, PhD; Qiang Li, MBiostat, BPH, AStat; Mehul Desai, MD; David R. Matthews, DPhil, BM, BCh; on behalf of the CANVAS Program collaborative group